Skip to main content
European Commission logo print header

TinniMizer : A Patient-specific Novel Approach for Tinnitus Treatment

Project description

Musical therapy for tinnitus

Tinnitus or ringing in the ears is the sensation of hearing sounds when no actual external noise is present. The severity of tinnitus is difficult to determine, and depending on the cause there are different treatment options available. However, there is no permanent cure yet, and sufferers often experience an inability to work or socialise, with obvious socioeconomic consequences. The EU-funded TinniMizer project has developed a musical therapy treatment which is cost-effective and easy to use. The system is expected to alleviate the negative impact of tinnitus after only 3 months of treatment compared to 1.5 years, which is the standard time of other sound therapy systems.


Tinnitus can be a debilitating condition, which negatively affects a patient’s overall health and social well-being. Even moderate cases can interfere with the ability to work and socialise. The financial consequences of tinnitus are significant. Personal economic loss to an individual with tinnitus--including lost earnings, productivity, and health expenses--can be up to €30,000 annually. The cost to society as a whole has been estimated at upwards of €26 billion annually. Despite these effects there is currently no scientifically proven cure for most cases of chronic tinnitus. The medical doctors (ENT specialists), audiologists, and electronics-biomedical engineers in Genmel Technology have developed a new, patient-specific, state-of-the-art, and patented musical therapy system called TinniMizer as a new treatment for Tinnitus due to a substantial need to cure the tinnitus with an easy-to-use and cost-effective therapeutic system. Preliminary results obtained from about 20 patients at three clinics (Tinnitus Treatment Centers) indicate that after using TinniMizer system for about 3 months, there is approximately 70% reduction in the complaints of tinnitus patients. Through this project, Genmel will further develop this therapy to result in over 95% reduction in tinnitus. In other sound therapy systems, the duration of therapy is 1.5 years. Our goal is to reduce this period to a much shorter period (up to 3 months). Genmel offers R&D solutions, productions, and consulting services especially in the field of Biomedical, Electronics, Medicine and Energy. Academicians, engineers and technicians are working in GENMEL. The main goal of GENMEL is to develop and bring to market new products, services and business models that could drive economic growth. Through this project, Genmel aims to achieve a total turnover of >€14.5 million by the 5th year of TinniMizer commercialization.

Call for proposal


See other projects for this call

Sub call




Net EU contribution
€ 50 000,00
Ciftehavuzlar mah. eski londra asfalti cad. kuluck erc1 blok 151/1e/105
34220 Istanbul

See on map


The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

İstanbul İstanbul İstanbul
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 21 429,00